Design of new CD38 inhibitors based on CoMFA modelling and molecular docking analysis of 4‑amino-8-quinoline carboxamides and 2,4-diamino-8-quinazoline carboxamides

References

• K.A. Frerichs, N.A. Nagy, P.L. Lindenbergh, P. Bosman, J.M. Soto, M. Broekmans, R.W.J. Groen, M. Themeli, L. Nieuwenhuis, C. Stege, I.S. Nijhof, T. Mutis, S. Zweegman, H.M. Lokhorst, and N.W.C.J. van de Donk, CD38-targeting antibodies in multiple myeloma: Mechanisms of action and clinical experience, Expert Rev. Clin. Immunol. 14 (2018), pp. 197–206.
   PubMed Web of Science ®Google Scholar
• G. Shubinsky and M. Schlesinger, The CD38 lymphocyte differentiation marker: New insight into its ectoenzymatic activity and its role as a signal transducer, Immunity 7 (1997), pp. 315–324.
   PubMed Web of Science ®Google Scholar
• Q. Liu, I.A. Kriksunov, R. Graeff, C. Munshi, H.C. Lee, and Q. Hao, Crystal structure of human CD38 extracellular domain, Structure 13 (2005), pp. 1331–1339.
   PubMed Web of Science ®Google Scholar
• S. Deaglio, S. Aydin, T. Vaisitti, L. Bergui, and F. Malavasi, CD38 at the junction between prognostic marker and therapeutic target, Trends Mol. Med. 14 (2008), pp. 210–218.
   PubMed Web of Science ®Google Scholar
• E. Ferrero and F. Malavasi, The metamorphosis of a molecule: From soluble enzyme to the leukocyte receptor CD38, J. Leukoc. Biol. 65 (1999), pp. 151–161.
   PubMed Web of Science ®Google Scholar
• S. Deaglio, T. Vaisitti, S. Serra1, V. Audrito, C. Bologna, G. D’Arena, L. Laurenti, D. Gottardi, and F. Malavasi, CD38 in chronic lymphocytic leukemia: From bench to bedside?, Mini Rev. Med. Chem. 11 (2011), pp. 503–507.
   PubMed Web of Science ®Google Scholar
• E.N. Chini, C.C.S. Chini, J.M.E. Netto, G.C. de Oliveira, and W. van Schooten, The pharmacology of CD38/NADase: An emerging target in cancer and diseases of aging, Trends Pharmacol. Sci. 39 (2018), pp. 424–436.
   PubMed Web of Science ®Google Scholar
• P. Aksoy, T.A. White, M. Thompson, and E.N. Chini, Regulation of intracellular levels of NAD: A novel role for CD38, Biochem. Biophys. Res. Commun. 345 (2006), pp. 1386–1392.
   PubMed Web of Science ®Google Scholar
• E.N. Chini, CD38 as a regulator of cellular NAD: A novel potential pharmacological target for metabolic conditions, Curr. Pharm. Des. 15 (2009), pp. 57–63.
   PubMed Web of Science ®Google Scholar
• A.B. Salmina, O. Lopatina, M.V. Ekimova, S.V. Mikhutkina, and H. Higashida, CD38/cyclic ADP-ribose system: A new player for oxytocin secretion and regulation of social behavior, J. Neuroendocrinol. 22 (2010), pp. 380–392.
   PubMed Web of Science ®Google Scholar
• L. Sun, J. Iqbal, S. Zaidi, L.L. Zhu, X. Zhang, Y. Peng, and M. Zaidi, Structure and functional regulation of the CD38 promoter, Biochem. Biophys. Res. Commun. 341 (2006), pp. 804–809.
   PubMed Web of Science ®Google Scholar
• E. Blacher, B.B. Baruch, A. Levy, N. Geva, K.D. Green, S. Garneau-Tsodikova, M. Fridman, and R. Stein, Inhibition of glioma progression by a newly discovered CD38 inhibitor, Int. J. Cancer 136 (2015), pp. 1422–1433.
   PubMed Web of Science ®Google Scholar
• B. Sepehri and R. Ghavami, The identification of new CD38 inhibitors by combined structure and ligand based virtual screening approaches of ZINC database, Lett. Drug Des. Discov. 15 (2018), pp. 654–660.
   Web of Science ®Google Scholar
• X.H. Guan, X. Hong, N. Zhao, X.H. Liu, Y.F. Xiao, T.T. Chen, L.B. Deng, X.L. Wang, J.B. Wang, G.J Ji, M. Fu, K.Y. Deng, and H.B. Xin, CD38 promotes angiotensin II-induced cardiac hypertrophy, J. Cell. Mol. Med. 21 (2017), pp. 1492–1502.
   PubMed Web of Science ®Google Scholar
• P. Aksoy, C. Escande, T.A. White, M. Thompson, S. Soares, J.C. Benech, and E.N. Chini, Regulation of SIRT 1 mediated NAD dependent deacetylation: A novel role for the multifunctional enzyme CD38, Biochem. Biophys. Res. Commun. 349 (2006), pp. 353–359.
   PubMed Web of Science ®Google Scholar
• J. Camacho-Pereira, M.G. Tarragó, C.C.S. Chini, V. Nin, C. Escande, G.M. Warner, A.S. Puranik, R.A. Schoon, J.M. Reid, A. Galina, and E.N. Chini, CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism, Cell Metab. 23 (2016), pp. 1127–1139.
   PubMed Web of Science ®Google Scholar
• N.W.C.J. van de Donk, M.L. Janmaat, T. Mutis, J.J.L. van Bueren, T. Ahmadi, A.K. Sasser, H.M. Lokhorst, and P.W.H.I. Parren, Monoclonal antibodies targeting CD38 in hematological malignancies and beyond, Immunol. Rev. 270 (2016), pp. 95–112.
   PubMed Web of Science ®Google Scholar
• B. Sepehri and R. Ghavami, Molecular docking and CoMFA studies of thiazoloquin(az)olin(on)es as CD38 inhibitors: Determination of inhibitory mechanism, pharmacophore interactions, and design of new inhibitors, J. Biomol. Struct. Dyn. 35 (2017), pp. 1890–1898.
   PubMed Web of Science ®Google Scholar
• S. Zhang, X. Xue, L. Zhang, L. Zhang, and Z. Liu, Comparative analysis of pharmacophore features and quantitative structure–activity relationships for CD38 covalent and non-covalent inhibitors, Chem. Biol. Drug Des. 86 (2015), pp. 1411–1424.
   PubMed Web of Science ®Google Scholar
• X. Gao and Y. Ren, Identification of thiazoloquin(az)olin(on)es derivatives as CD38 inhibitors through 3D-QSAR and molecular docking simulations, Lett. Drug Des. Discov. 14 (2017), pp. 175–185.
   Web of Science ®Google Scholar
• J.D. Becherer, E.E. Boros, T.Y. Carpenter, D.J. Cowan, D.N. Deaton, C.D. Haffner, M.R. Jeune, I.W. Kaldor, J.C. Poole, F. Preugschat, T.R. Rheault, C.A. Schulte, B.G. Shearer, T.W. Shearer, L.M. Shewchuk, T.L. Smalley Jr, E.L. Stewart, J.D. Stuart, and J.C. Ulrich, Discovery of 4‑amino-8-quinoline carboxamides as novel, submicromolar inhibitors of NAD-hydrolyzing enzyme CD38, J. Med. Chem. 58 (2015), pp. 7021–7056.
   PubMed Web of Science ®Google Scholar
• D.N. Deaton, C.D. Haffner, B.R. Henke, M.R. Jeune, B.G. Shearer, E.L. Stewart, J.D. Stuart, and J.C. Ulrich, 2,4-Diamino-8-quinazoline carboxamides as novel, potent inhibitors of the NAD hydrolyzing enzyme CD38: Exploration of the 2-position structure–activity relationships, Bioorg. Med. Chem. 26 (2018), pp. 2107–2150.
   PubMed Web of Science ®Google Scholar
• M.F. Andrada, E.G. Vega-Hissi, M.R. Estrada, and J.C.G. Martinez, Impact assessment of the rational selection of training and test sets on the predictive ability of QSAR models, SAR QSAR Environ. Res. 28 (2017), pp. 1011–1023.
   PubMed Web of Science ®Google Scholar
• HyperChem 7.1. Hypercube, Inc., Gainesville,  USA; software available at http://www.hyper.com.
   Google Scholar
• M. O'Boyle, C.A. James Banck, T. Vandermeersch, and G.R Hutchison, Open babel: an open chemical toolbox, Int.J. Cheminform. 3 (2001), 33. doi:10.1186/1758-2946-3-33.
   Google Scholar
• P. Tosco and T. Balle, Open3DALIGN 2.27 software available at http://open3dalign.sourceforge.net.
   Google Scholar
• P. Tosco, T. Balle, and F. Shiri, Open3DALIGN: An open-source software aimed at unsupervised ligand alignment, J. Comput. Aided Mol. Des. 25 (2011), pp. 777–783.
   PubMed Web of Science ®Google Scholar
• P. Tosco and T. Balle, Open3DQSAR 2.282 software available at http://open3dqsar.sourceforge.net.
   Google Scholar
• P. Tosco and T. Balle, Open3DQSAR: A new open-source software aimed at high-throughput chemometric analysis of molecular interaction fields, J. Mol. Model. 17 (2001), pp. 201–208.
   Google Scholar
• Schrödinger, PyMOL (1.7.0.0).New York, USA; software available at http://www.pymol.org.
   Google Scholar
• MGLTools 1.5.6, Molecular Graphics Laboratory (MGL) of the Scripps Research Institute,  La Jolla, USA, 2012; software available at http://mgltools.scripps.edu.
   Google Scholar
• O. Trott and A.J. Olson, AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J. Comput. Chem. 31 (2010), pp. 455–461.
   PubMed Web of Science ®Google Scholar
• O. Trott and A.J. Olson, AutoDock Vina 1.1.2; software available at http://vina.scripps.edu/.
   Google Scholar
• Discovery Studio 16.1.0; , Accelrys, BIOVIA, San Diego, USA; software available at www.accelrys.com.
   Google Scholar
• N.J. Richmond, P. Willett, and R.D. Clark, Alignment of three-dimensional molecules using an image recognition algorithm, J. Mol. Graph. Model. 23 (2004), pp. 199–209.
   PubMed Web of Science ®Google Scholar
• G. Cruciani, Molecular Interaction Fields: Applications in Drug Discovery and ADME Prediction, Wiley, Weinheim, 2006.
   Google Scholar
• M.A. Kastenholz, M. Pastor, G. Cruciani, E.E.J. Haaksma, and T. Fox, GRID/CPCA: A new computational tool to design selective ligands, J. Med. Chem. 43 (2000), pp. 3033–3044.
   PubMed Web of Science ®Google Scholar
• M. Pastor, G. Cruciani, and S. Clementi, Smart region definition: A new way to improve the predictive ability and interpretability of three-dimensional quantitative structure-activity relationships, J. Med. Chem. 40 (1997), pp. 1455–1464.
   PubMed Web of Science ®Google Scholar
• M. Baroni, G. Costantino, G. Cruciani, D. Riganelli, R. Valigi, and S. Clementi, Generating optimal linear PLS estimations (GOLPE): An advanced chemometric tool for handling 3D-QSAR problems, Mol Inform. 12 (1993), pp. 9–20.
   Google Scholar
• B. Sepehri, N. Omidikia, M. Kompany-Zareh, and R. Ghavami, Predictive and descriptive CoMFA models: The effect of variable selection, Comb. Chem. High Throughput Screen. 21 (2018), pp. 117–124.
   PubMed Web of Science ®Google Scholar
• B. Sepehri and R. Ghavami, Design new P-glycoprotein modulators based on molecular docking and CoMFA study of a, b-unsaturated carbonyl-based compounds and oxime analogs as anticancer agents, J. Mol. Struct. 1130 (2017), pp. 922–928.
   Web of Science ®Google Scholar
• A. Golbraikh and A. Tropsha, Beware of q2!, J. Mol. Graph. Model. 20 (2002), pp. 269–276.
   PubMed Web of Science ®Google Scholar
• G. Melagraki and A. Afantitis, Enalos KNIME nodes: Exploring corrosion inhibition of steel in acidic medium, Chemom. Intel. Lab. 123 (2013), pp. 9–14.
   Web of Science ®Google Scholar
• G. Melagraki and A. Afantitis, Enalos InSilicoNano platform: An online decision support tool for the design and virtual screening of nanoparticles, RSC Adv. 4 (2014), pp. 50713–50725.
   Web of Science ®Google Scholar
• P.K. Ojha, I. Mitra, R.N. Das, and K. Roy, Further exploring rm2 metrics for validation of QSPR models, Chemom. Intell. Lab. 107 (2011), pp. 194–205.
   Web of Science ®Google Scholar
• A. Tropsha, Best practices for QSAR model development, validation, and exploitation, Mol. Inf. 29 (2010), pp. 476–488.
   PubMed Web of Science ®Google Scholar
• J.F. Aranda, D.E. Bacelo, M.S. Leguizamón Aparicio, M.A. Ocsachoque, E.A. Castro, and P.R. Duchowicz, Predicting the bioconcentration factor through a conformation-independent QSPR study, SAR QSAR Environ. Res. 28 (2017), pp. 749–763.
   PubMed Web of Science ®Google Scholar
• F. Sahigara, K. Mansouri, D. Ballabio, A. Mauri, V. Consonni, and R. Todeschini, Comparison of different approaches to define the applicability domain of QSAR models, Molecules 17 (2012), pp. 4791–4810.
   PubMed Web of Science ®Google Scholar
• D. Gadaleta, G.F. Mangiatordi, M. Catto, A. Carotti, and O. Nicolotti, Applicability domain for QSAR models: Where theory meets reality, Int. J. Quant. Struct.-Prop. Relat. 1 (2016), pp. 45–63.
   Google Scholar
• B. Sepehri, M. Rezaei, and R. Ghavami, The in silico identification of potent anti-cancer agents by targeting the ATP binding site of the N-domain of HSP90, SAR QSAR Environ, Res. 29 (2018), pp. 551–565.
   PubMed Web of Science ®Google Scholar